Want to see JP:4563 full AI Analyst Report?

AnGes (4563) Price & Analysis

1 Followers

4563 Stock Chart & Stats

¥47.00

¥0.00(0.00%)

At close: Jul 27 4:00 PM EDT

¥47.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥44.00 - ¥120.00

Previous CloseN/A

Volume237.70K

Average Volume (3M)3.22M

Market Cap

¥18.75B

Enterprise Value¥18.05B

Total Cash (Recent Filing)¥835.88M

Total Debt (Recent Filing)¥688.34M

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-14.10

Shares Outstanding398,835,540

10 Day Avg. Volume1,701,110

30 Day Avg. Volume3,216,076

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)7.04

Price to Sales (P/S)24.76

P/FCF Ratio-3.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Pipeline Monetization / Licensing ModelAnGes' core model focuses on R&D and monetizing candidates through collaborations, milestone/royalty deals and partner-funded development. This durable model lowers need for large commercial infrastructure, can generate non-dilutive milestone cash and extend runway while programs advance.

Low Leverage / Financial FlexibilityLow debt relative to equity gives the company financial flexibility typical for small biotechs: less interest burden, more capacity to absorb R&D spending, and greater headroom to raise capital or negotiate partnerships without near-term solvency pressure, a durable advantage over months.

Improving Revenue MomentumReported top-line acceleration indicates growing collaboration or licensing receipts and stronger commercial traction. Sustained revenue growth improves funding prospects, supports continuing development spend, and can reduce reliance on dilutive financings if momentum persists over the next several quarters.

Bears Say

Persistent Cash BurnThe company records deeply negative operating and free cash flow annually, creating a persistent funding need. Over 2–6 months this structural cash burn raises financing and dilution risk, can force compressed deal terms or timetable changes, and constrains discretionary R&D investments.

Ongoing Operating LossesConsistent operating losses mean the business cannot self-fund its development programs. This persistent unprofitability increases dependency on partners or capital markets, limits strategic optionality, and makes long-term planning sensitive to fundraising success rather than operational cash generation.

Eroding Balance SheetDeclining assets and equity indicate that cumulative losses are eroding capitalization. A weakening balance sheet reduces resilience to adverse shocks, raises cost of capital and may constrain bargaining power in licensing or partnership talks, creating a sustained financing vulnerability.

4563 FAQ

What was AnGes Inc’s price range in the past 12 months?

AnGes Inc lowest stock price was ¥44.00 and its highest was ¥120.00 in the past 12 months.

What is AnGes Inc’s market cap?

AnGes Inc’s market cap is ¥18.75B.

When is AnGes Inc’s upcoming earnings report date?

AnGes Inc’s upcoming earnings report date is Aug 07, 2026 which is in 8 days.

How were AnGes Inc’s earnings last quarter?

AnGes Inc released its earnings results on May 08, 2026. The company reported -¥2.74 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.74.

Is AnGes Inc overvalued?

According to Wall Street analysts AnGes Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AnGes Inc pay dividends?

AnGes Inc does not currently pay dividends.

What is AnGes Inc’s EPS estimate?

AnGes Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AnGes Inc have?

AnGes Inc has 398,835,540 shares outstanding.

What happened to AnGes Inc’s price movement after its last earnings report?

AnGes Inc reported an EPS of -¥2.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.923%.

Which hedge fund is a major shareholder of AnGes Inc?

Currently, no hedge funds are holding shares in JP:4563

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AnGes Inc

AnGes, Inc. (4563) is a Japanese biotechnology company focused on developing and commercializing nucleic-acid–based medicines and gene therapies. The company’s activities center on research and development, clinical development, regulatory work, and potential out-licensing of drug candidates, with a portfolio historically associated with DNA plasmid–based therapeutics and other genetic medicine approaches. null